Navigation Links
Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75
Date:11/3/2009

========== Gross margin (4) ---------------- Product $2,551.9 $139.1 5.8% $2,412.8 Product gross margin percentage 5.8% -0.6% 6.4% Service $447.9 $102.3 29.6% $345.6 Service gross margin percentage 72.0% 1.8% 70.2% Total $2,999.8 $241.4 8.8% $2,758.4 Total gross margin percentage 6.7% -0.5% 7.2% * Not meaningful. (1) Includes majority-owned Europa Apotheek Venlo's operating results commencing on the April 28, 2008 acquisition date. (2) Includes retail co-payments of $2,115 million and $1,828 million for the third quarters of 2009 and 2008, and $6,487 million and $5,830 million for the nine months of 2009 and 2008. (3) Please refer to Table 8 for reconciliation of the earnings per share excluding intangible amortization. (4) Defined as net revenues minus cost of revenues. Medco Health Solutions, Inc. Consolidated Selected Information (Unaudited) (In millions) Table 5. Quarter Ended Quarter Ended September 26, September 27, 2009 Variance 2008 -------------- ----------- -------------- Volume Information ------------------ Retail prescriptions 144.3 29.2 25.4% 115.1 Mail-order prescriptions 25.5 (0.6) -2.3% 26.1 -------------- ------ ---- -------------- Total prescriptions 169.8 28.6 20.3% 141.2
'/>"/>
SOURCE Medco Health Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Medco to Present at November 2009 Investor Conferences
2. The Medco Foundation Joins With the Entertainment Industry Foundation to Give Health a Hand to Communities in Need
3. Medcos 2010 Medicare Prescription Drug Plan Helps People Take an Active Part in Lowering Prescription Costs
4. Medco Announces Date for Third-Quarter 2009 Financial Results; Company to Provide 2010 Earnings Guidance
5. Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children
6. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
7. Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation
8. Hoviones TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
9. Vtech(R) Delivers Todays Hottest Trends to Tech-Savvy Kids
10. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009).... 2 Novartis announced today that ...n Tasigna® (nilotinib) 200 mg capsules in a f...trength of the company,s hematology portfolio in a..., at the 51st American Society of Hematology (ASH)...any,s current therapies and investigational agents...
(Date:12/1/2009)...ire/ -- Reportlinker.com announces that a new mark...,, Medical Oxygen Systems - Global Market Opp...164334/Medical-Oxygen-Systems---Global-Market-Oppo...tems market for home healthcare setting is reckone...th expectations stem from demographic factors such...
(Date:12/1/2009)...ire/ -- Reportlinker.com announces that a new mark...,, Molecular Diagnostics - A World Market Revi...lecular-Diagnostics---A-World-Market-Review.html ... by several growth factors that include the need f...combine optimized sample preparation, analysis, an...
Breaking Medicine Technology:Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 2Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 3Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 4Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 5Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 6Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 7Reportlinker Adds Molecular Diagnostics - A World Market Review 2Reportlinker Adds Molecular Diagnostics - A World Market Review 3Reportlinker Adds Molecular Diagnostics - A World Market Review 4Reportlinker Adds Molecular Diagnostics - A World Market Review 5Reportlinker Adds Molecular Diagnostics - A World Market Review 6LifeNet Health Announces First Bio Implant with New Preservation Technology 6088 1LifeNet Health Announces First Bio Implant with New Preservation Technology 6088 2RBC Life Sciences Ranked as One of the Top 100 Workplaces in the Dallas Fort Worth Area 6084 1RBC Life Sciences Ranked as One of the Top 100 Workplaces in the Dallas Fort Worth Area 6084 2Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 1Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 2Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 3Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 4Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 5Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 6Once Daily INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets Now Available in Pharmacies Nationwide 6079 7
... EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Jun 6, 200...nnounced today that two,abstracts exploring Phase ...fe in treatment-failure gout patients will be,pres...ULAR) 2007,Annual Congress taking place June 13 - ...recombinant porcine urate oxidase currently,in Pha...
... SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio ...development of DNA vaccines,for cancers and infect...o treat localized cancers, announced today that th... positive interim,safety and tolerability data on ... using Inovio,s electroporation technology for,int...
Other Medicine Technology:Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress 2Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress 3Savient Pharmaceuticals Announces Acceptance of Two Gout-Related,Abstracts for Poster Presentation at the European League Against,Rheumatism (EULAR) 2007 Annual Congress 4Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 2Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 3Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 4Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 5
(Date:12/2/2009)...Leading medical device software engineering consul...13485 certification. A relatively few medical devi...ally achieved ISO 13485 certification. Many medica...dhere to other ISO standards as well. However, it ...ineering consulting firm to achieve the rigorous q...
(Date:12/2/2009)...2 Targeted breast ultra... lumps, is a safe, reliable and cost-effective alt...40, according to the findings of two studies prese...al Society of North America (RSNA). ,, "By perf...ce the number of expensive and avoidable invasive ...
(Date:12/2/2009)...rge-scale clinical trial presented today at the an...America (RSNA) provide the first strong evidence o...omen with dense breasts who are at elevated risk f... that MRI is highly sensitive in depicting early b...with ultrasound in addition to mammography signifi...
(Date:12/1/2009)..., Dec. 1 Reportlinker.com announce...n its catalogue: ,, Emerging Clinical Trial L... healthcare and regulatory environment ,, ht...al-Trial-Locations---India-Market-dynamics-and-the...ml ,, Over the last decade pharmaceutical and ...
(Date:12/1/2009)..., Dec. 1 A scientist wh... pain -- and ways we can control and relieve it --...yer Award for Psychology. ,, Ronald Melzack, ps...n Montreal, was selected for the award from among ...point of injury but instead in their brain through...
Breaking Medicine News(10 mins):Health News:Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification 2Health News:Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 2Health News:Annual screening with breast ultrasound or MRI could benefit some women 2Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Health News:Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Health News:Scientist Who Helps Explain Pain Wins Grawemeyer Award 2
...ally take anti-inflammatory drugs to treat osteoar... side effects. Of late, people are switching over ... A recent study investigated the efficacy of a...n the November2006 issue of Arthritis & Rheumatism...
...n the Netherlands capital have increased security ...with broken bones under mysterious circumstances//...bies were found last week at the city's Free Unive...who had been in hospital since birth was found wit...
...ilize a debt ridden NHS hospital's radiotherapy de...criticism from the union and the conservatives//. ...ch hospital in Suffolk, suggestions came in from t...rding to the calculations made by the managers, th...
...ong the known value adds of vegetables, this one r... and aging has shown that eating vegetables is a s...which may even retrograde any signs of dementia re... servings of vegetables were nearly five years you...
...ment of pride of people of the Ottawa region when ...Mental Health Centre which offers// psychiatric c...on, 400,000-square-foot facility puts 188 inpatien... $132 million, 400,000-square-foot hospital can ac...
...alf of Chinese middle-aged men show symptoms of de...weating as well as a fading interest// in sex beca... The online survey released Thursday found that 52...ine. The survey was conducted by the Beijing ...
Other Medicine News:Health News:Acupuncture for chronic pain in Osteoarthritis patients 2Health News:Pet Peeves: Conservatives Howl at Proposal to Share NHS Hosp by Pets and People 2
Tying Forceps - Curved
Nordan Straight Tying Forceps
McPherson Angled Tying Forceps
Clayman - McPherson Angled Tying Forceps
Medicine Products: